2019
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, Robertson M, Haber B. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal Of Viral Hepatitis 2019, 26: 329-336. PMID: 30412325, DOI: 10.1111/jvh.13037.Peer-Reviewed Original ResearchMeSH KeywordsAmidesAntiviral AgentsBenzofuransCarbamatesCyclopropanesData Interpretation, StatisticalFemaleGenotypeHepacivirusHepatitis C, ChronicHumansImidazolesMalePredictive Value of TestsQuinoxalinesReproducibility of ResultsSensitivity and SpecificitySulfonamidesSustained Virologic ResponseViral LoadConceptsBaseline viral loadResistance-associated substitutionsNS5A resistance-associated substitutionsEBR/GZRElbasvir/grazoprevirGenotype 1a infectionViral loadNegative predictive valuePositive predictive valuePredictive valueBaseline NS5a resistance-associated substitutionsHepatitis C virus infectionPoor negative predictive valueEuropean treatment guidelinesC virus infectionSustained virologic responseHigh positive predictive valueEBR 50GT1a infectionVirologic failureVirologic responseTreatment guidelinesTreatment outcomesVirus infectionStratification factors
2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals Of Internal Medicine 2016, 165: 625-634. PMID: 27537841, DOI: 10.7326/m16-0816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsBenzofuransBuprenorphineBuprenorphine, Naloxone Drug CombinationDouble-Blind MethodDrug CombinationsDrug Resistance, ViralFemaleGenotypeHepatitis C, ChronicHumansImidazolesMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersQuinoxalinesRecurrenceSubstance Abuse, IntravenousYoung AdultConceptsDeferred-treatment groupOpioid agonist therapyImmediate treatment groupHepatitis C virus infectionC virus infectionElbasvir-grazoprevirDrug useProbable reinfectionAgonist therapyHCV infectionViral recurrenceAdverse eventsVirus infectionChronic HCV genotype 1Double-blind trialGenotype 3 infectionTreatment-naive patientsHCV genotype 1Interferon-free HCV treatmentOngoing drug useVirologic responseHCV therapyHCV treatmentPrimary outcomeGenotype 1